Ardelyx Slashes IBSRELA Guidance by $60M Despite Record Q2 Revenue
ARDX is trading near its 52-week low of $4.71 (13% below the low).
Summary
Ardelyx posted record Q2 product revenue of $118.1M, up 31% year-over-year, but IBSRELA sales missed internal expectations due to aggressive payor utilization management. The company cut its full-year 2026 IBSRELA revenue guidance by $60M to $350M-$370M, while reiterating XPHOZAH guidance of $110M-$120M. This follows a $50M debt draw in July and a recent equity incentive plan expansion, signaling cash needs amid growth headwinds. The stock, already trading near its 52-week low, faces pressure from the guidance cut despite narrowing net losses to $16.7M. Operating expenses are expected below $500M for the year, providing some cost control.
At the time of this announcement, ARDX was trading at $4.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.71 to $8.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.